Eleonora Carosa

Eleonora Carosa

Auto-generated profile, based on publicly available information

Eleonora Carosa

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2005 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
CCCesare Carani
Cesare Carani
AIAndrea M. Isidori
Andrea M. Isidori
AGAntonio Granata
Antonio Granata
ECEleonora Carosa
Eleonora Carosa
MMMario Maggi
Mario Maggi
Emmanuele A. JanniniEmmanuele A. Jannini
Emmanuele A. Jannini
Thyroid hormones have a dramatic effect on human behavior. However, their role on sexual behavior and performance has seldom been investigated in men. The objective of this study was to evaluate the prevalence of sexual dysfunctions in patients with hyper- and hypothyroidism and their resolution after normalization of thyroid hormone levels. We conducted a multicenter prospective study at endocrinology and andrology clinics in university hospitals. The study included 48 adult men, 34 with hyperthyroidism and 14 with hypothyroidism. Subjects were screened for hypoactive sexual desire (HSD), erectile dysfunction (ED), premature ejaculation (PE), and delayed ejaculation (DE) on presentation and 8-16 wk after recovery from the thyroid hormone disorder. In hyperthyroid men, HSD, DE, PE, and ED prevalence was 17.6, 2.9, 50, and 14.7%, whereas in hypothyroid men, the prevalence of HSD, DE, and ED was 64.3% and of PE was 7.1%. After thyroid hormone normalization in hyperthyroid subjects, PE prevalence fell from 50 to 15%, whereas DE was improved in half of the treated hypothyroid men. Significant changes were found in the subdomains of the International Index of Erectile Function; ejaculation latency time doubled after treatment of hyperthyroidism (from 2.4 +/- 2.1 to 4.0 +/- 2.0 min), whereas for hypothyroid men it declined significantly, from 21.8 +/- 10.9 to 7.4 +/- 7.2 (P < 0.01 for both). TSH and thyroid hormone levels normalized rapidly after treatment, and changes in circulating sex steroids partially reflected the changes in SHBG levels. In summary, most patients with thyroid hormone disorders experience some sexual dysfunctions, which can be reversed by normalizing thyroid hormone levels. Despite the associated changes in sex hormone levels, the high prevalence of ejaculatory disorders and their prompt reversibility suggest a direct involvement of thyroid hormones in the physiology of ejaculation.

1 April 2007 in Neoplasia
Verified
Journal Article
Open access
DMDanilo Millimaggi
Danilo Millimaggi
MMMarianna Mari
Marianna Mari
SDSandra D'Ascenzo
Sandra D'Ascenzo
ECEleonora Carosa
Eleonora Carosa
Emmanuele A. JanniniEmmanuele A. Jannini
Emmanuele A. Jannini
VDVincenza Dolo
Vincenza Dolo
Matrix metalloproteinase (MMP) degradation of extracellular matrix is thought to play an important role in invasion, angiogenesis, tumor growth, and metastasis. Several studies have demonstrated that CD147/extracellular MMP inducer, a membrane-spanning molecule highly expressed in tumor cells, may be involved in the progression of malignancies by regulating expression of MMP in peritumoral stromal cells. In the present study we show that CD147 is expressed in microvesicles derived from epithelial ovarian cancer cells and that CD147-positive vesicles may promote an angiogenic phenotype in endothelial cells in vitro. Vesicles shed by human ovarian carcinoma cell lines OVCAR3, SKOV3, and A2780 expressed different levels of CD147 and stimulated proangiogenic activities of human umbilical vein endothelial cells (HUVECs) in a CD147-dependent fashion (OVCAR3 > SKOV3 > A2780). Moreover, vesicles shed by ovarian carcinoma cell line CABA I with low CD147 expression had no significant effect on the development of angiogenic phenotype in HUVECs. The treatment of OVCAR3 cells with small interfering RNA against CD147 suppressed the angiogenic potential of OVCAR3-derived microvesicles. However, transfection of CD147 cDNA into the CABA I cell line enabled CABA I-derived vesicles to induce angiogenesis and to promote MMP genes expression in HUVECs. We therefore conclude that vesicles shed by ovarian cancer cells may induce proangiogenic activities of HUVECs by a CD147-mediated mechanism.

1 August 2001 in Urology
Verified
Journal Article
Closed access
ESEmiliano Screponi
Emiliano Screponi
ECEleonora Carosa
Eleonora Carosa
SSSavino M Di Stasi
Savino M Di Stasi
MPMario Pepe
Mario Pepe
GCGiuseppe Carruba
Giuseppe Carruba
Emmanuele A. JanniniEmmanuele A. Jannini
Emmanuele A. Jannini

24 December 1999 in International Journal of Andrology
Verified
Journal Article
Open access
PDF file
Emmanuele A. JanniniEmmanuele A. Jannini
Emmanuele A. Jannini
ESEmiliano Screponi
Emiliano Screponi
ECEleonora Carosa
Eleonora Carosa
MPMario Pepe
Mario Pepe
FGFrancesco Lo Giudice
Francesco Lo Giudice
SBSalvatore Benvenga
Salvatore Benvenga
The role of androgenic hormones in human sexuality, in the mechanism of erection and in the pathogenesis of impotence is under debate. While the use of testosterone is common in the clinical therapy of male erectile dysfunction, hypogonadism is a rare cause of impotence. We evaluated serum testosterone levels in men with erectile dysfunction resulting either from organic or non‐organic causes before and after non‐hormonal impotence therapy. Eighty‐three consecutive cases of impotence (70% organic, 30% non‐organic, vascular aetiology being the most frequent) were subjected to hormonal screening before and after various psychological, medical (prostaglandin E1, yohimbine) or mechanical therapies (vascular surgery, penile prostheses, vacuum devices). Thirty age‐matched healthy men served as a control group. Compared to controls, patients with impotence resulting from both organic and non‐organic causes showed reduced serum levels of both total testosterone (11.1 ± 2.4 vs. 17.7 ± 5.5 nmol/L) and free testosterone (56.2 ± 22.9 vs. 79.4 ± 27.0 pmol/L) (both p < 0.001). Irrespective of the different aetiologies and of the various impotence therapies, a dramatic increase in serum total and free testosterone levels (15.6 ± 4.2 nmol/L and 73.8 ± 22.5 pmol/L, respectively) was observed in patients who achieved normal sexual activity 3 months after commencing therapy (p < 0.001). On the contrary, serum testosterone levels did not change in patients in whom therapies were ineffective. Since the pre‐therapy low testosterone levels were independent of the aetiology of impotence, we hypothesize that this hormonal pattern is related to the loss of sexual activity, as demonstrated by its normalization with the resumption of coital activity after different therapies. The corollary is that sexual activity may feed itself throughout the increase in testosterone levels.

1 March 2008 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
GGGiovanni Luca Gravina
Giovanni Luca Gravina
FBFulvia Brandetti
Fulvia Brandetti
PMPaolo Martini
Paolo Martini
ECEleonora Carosa
Eleonora Carosa
SSSavino M. Di Stasi
Savino M. Di Stasi
Emmanuele A. JanniniEmmanuele A. Jannini
Emmanuele A. Jannini

3 September 2004 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
ECEleonora Carosa
Eleonora Carosa
PMPaolo Martini
Paolo Martini
FBFulvia Brandetti
Fulvia Brandetti
SSSavino M. Di Stasi
Savino M. Di Stasi
FLFrancesco Lombardo
Francesco Lombardo
Emmanuele A. JanniniEmmanuele A. Jannini
Emmanuele A. Jannini